OOIR: Observatory of International Research

Papers

(The H4-Index of Biomarker Research is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma	149
Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases	144
The spatial impact of a Western diet in enriching Galectin-1-regulated Rho, ECM, and SASP signaling in a novel MASH-HCC mouse model	124
CardioAtlas: deciphering the single-cell transcriptome landscape in cardiovascular tissues and diseases	121
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors	115
Exosomal PSM-E inhibits macrophage M2 polarization to suppress prostate cancer metastasis through the RACK1 signaling axis	106
Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma	99
Mitochondrial transfer in hematological malignancies	97
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients	96
Advances in the DNA methylation hydroxylase TET1	96
Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer	90
Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology	87
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes	85
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma	79
Dynamic changes of bone microarchitecture and volumetric mineral density assessed by HR-pQCT in patients with cervical cancer after concurrent chemoradiotherapy: a prospective study	76
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends	71
p53 biology and reactivation for improved therapy in MDS and AML	67
Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy	61
Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions	59
Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC	58
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells	57
Monocyte-macrophages modulate intestinal homeostasis in inflammatory bowel disease	54
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy	54
Donor T cells for CAR T cell therapy	53
Unveiling the potential of CLL-1: a promising target for AML therapy	52

The overlooked trio: sleep duration, sampling time and physical exercise alter levels of olink-assessed blood biomarkers of cardiovascular risk	50
Targeting interleukin-1β and inflammation in lung cancer	47
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients	47
Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer	47
STAT3–mediated up-regulation of DAB2 via SRC-YAP1 signaling axis promotes Helicobacter pylori-driven gastric tumorigenesis	46
The role and metabolic adaptations of neutrophils in premetastatic niches	45
Correction: Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities	45
Dysregulation of plasma circulating microRNAs in all-cause and cause-specific cancers: the Rotterdam Study	45
RUNX1 promotes angiogenesis in colorectal cancer by regulating the crosstalk between tumor cells and tumor associated macrophages	43
Multiple regulatory events contribute to a widespread circular RNA downregulation in precancer and early stage of colorectal cancer development	42
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics	42
The role of BATF in immune cell differentiation and autoimmune diseases	42
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy	41
Correction: Long non-coding RNA SLC25A21-AS1 inhibits the development of epithelial ovarian cancer by specifically inducing PTBP3 degradation	41
Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer	40
Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer	40
The involvement of krüppel-like transcription factor 2 in megakaryocytic differentiation induction by phorbol 12-myrestrat 13-acetate	40